Annual report
2590.TEDINET S100XYDT
Period2025-01-21 → 2026-01-20
Filed2026-04-14
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥241.2bn | 2025-01-21 → 2026-01-20 | Cons. | Net sales |
| Revenue | ¥237.2bn | 2024-01-21 → 2025-01-20 | Cons. | Net sales |
| Revenue | ¥213.4bn | 2023-01-21 → 2024-01-20v | Cons. | Net sales (5-year summary) |
| Revenue | ¥160.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net sales (5-year summary) |
| Revenue | ¥162.6bn | 2021-01-21 → 2022-01-20d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.2bn | 2025-01-21 → 2026-01-20 | Cons. | Operating income |
| Operating income | ¥4.8bn | 2024-01-21 → 2025-01-20 | Cons. | Operating income |
| Ordinary income | ¥1.5bn | 2025-01-21 → 2026-01-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.0bn | 2024-01-21 → 2025-01-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2023-01-21 → 2024-01-20v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥591m | 2022-01-21 → 2023-01-20v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.7bn | 2021-01-21 → 2022-01-20d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥27.8bn | 2025-01-21 → 2026-01-20 | Cons. | Income before income taxes |
| Profit before tax | ¥7.9bn | 2024-01-21 → 2025-01-20 | Cons. | Income before income taxes |
| Net income (owners) | −¥30.3bn | 2025-01-21 → 2026-01-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.8bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.4bn | 2023-01-21 → 2024-01-20v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥507m | 2022-01-21 → 2023-01-20v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.0bn | 2021-01-21 → 2022-01-20d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥31.3bn | 2025-01-21 → 2026-01-20 | Cons. | Profit loss |
| Net income | ¥3.4bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss |
| Total assets | ¥162.8bn | at 2026-01-20 | Cons. | Assets |
| Total assets | ¥185.2bn | at 2025-01-20 | Cons. | Assets |
| Total assets | ¥177.6bn | at 2024-01-20v | Cons. | Total assets (5-year summary) |
| Total assets | ¥164.2bn | at 2023-01-20v | Cons. | Total assets (5-year summary) |
| Total assets | ¥159.0bn | at 2022-01-20d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥97.9bn | at 2026-01-20 | Cons. | Liabilities |
| Total liabilities | ¥91.7bn | at 2025-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥64.9bn | at 2026-01-20 | Cons. | Net assets |
| Net assets / equity | ¥93.5bn | at 2025-01-20 | Cons. | Net assets |
| Net assets / equity | ¥91.5bn | at 2024-01-20v | Cons. | Net assets |
| Net assets / equity | ¥84.1bn | at 2023-01-20v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥83.3bn | at 2022-01-20d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥28.0bn | at 2026-01-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥30.7bn | at 2025-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥27.9bn | at 2026-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2025-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.7bn | at 2024-01-20v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.2bn | at 2023-01-20v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥30.1bn | at 2022-01-20d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥11.4bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.8bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.1bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥12.1bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.6bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.0bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.5bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥300m | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-957.83 | 2025-01-21 → 2026-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.66 | 2024-01-21 → 2025-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.77 | 2023-01-21 → 2024-01-20v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-16.2 | 2022-01-21 → 2023-01-20v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.1 | 2021-01-21 → 2022-01-20d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,028.83 | at 2026-01-20 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,908.51 | at 2025-01-20 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,843.99 | at 2024-01-20v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,663.79 | at 2023-01-20v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,645.36 | at 2022-01-20d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 39.5% | at 2026-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.6% | at 2025-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2024-01-20v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.9% | at 2023-01-20v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.1% | at 2022-01-20d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -38.8% | 2025-01-21 → 2026-01-20 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2024-01-21 → 2025-01-20 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2023-01-21 → 2024-01-20v | Cons. | Rate of return on equity (5-year summary) |
| ROE | -0.6% | 2022-01-21 → 2023-01-20v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2021-01-21 → 2022-01-20d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,375 | at 2026-01-20 | Cons. | Number of employees |
| Employees | 5,555 | at 2025-01-20 | Cons. | Number of employees |
| Employees | 5,182 | at 2024-01-20v | Cons. | Number of employees |
| Employees | 4,122 | at 2023-01-20v | Cons. | Number of employees |
| Employees | 4,029 | at 2022-01-20d | Cons. | Number of employees |
| Revenue | ¥5.0bn | 2025-01-21 → 2026-01-20 | Standalone | Operating revenue1 |
| Revenue | ¥5.4bn | 2024-01-21 → 2025-01-20 | Standalone | Operating revenue1 |
| Revenue | ¥5.3bn | 2023-01-21 → 2024-01-20v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥5.0bn | 2022-01-21 → 2023-01-20v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥4.8bn | 2021-01-21 → 2022-01-20d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥831m | 2025-01-21 → 2026-01-20 | Standalone | Operating income |
| Operating income | ¥972m | 2024-01-21 → 2025-01-20 | Standalone | Operating income |
| Ordinary income | ¥938m | 2025-01-21 → 2026-01-20 | Standalone | Ordinary income |
| Ordinary income | ¥1.4bn | 2024-01-21 → 2025-01-20 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2023-01-21 → 2024-01-20v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.3bn | 2022-01-21 → 2023-01-20v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-01-21 → 2022-01-20d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥25.8bn | 2025-01-21 → 2026-01-20 | Standalone | Income before income taxes |
| Profit before tax | ¥4.2bn | 2024-01-21 → 2025-01-20 | Standalone | Income before income taxes |
| Net income | −¥26.1bn | 2025-01-21 → 2026-01-20 | Standalone | Profit loss |
| Net income | ¥3.1bn | 2024-01-21 → 2025-01-20 | Standalone | Profit loss |
| Net income | ¥2.9bn | 2023-01-21 → 2024-01-20v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.9bn | 2022-01-21 → 2023-01-20v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.4bn | 2021-01-21 → 2022-01-20d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥97.4bn | at 2026-01-20 | Standalone | Assets |
| Total assets | ¥126.0bn | at 2025-01-20 | Standalone | Assets |
| Total assets | ¥124.8bn | at 2024-01-20v | Standalone | Total assets (5-year summary) |
| Total assets | ¥122.7bn | at 2023-01-20v | Standalone | Total assets (5-year summary) |
| Total assets | ¥122.2bn | at 2022-01-20d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥40.6bn | at 2026-01-20 | Standalone | Liabilities |
| Total liabilities | ¥43.3bn | at 2025-01-20 | Standalone | Liabilities |
| Net assets / equity | ¥56.7bn | at 2026-01-20 | Standalone | Net assets |
| Net assets / equity | ¥82.6bn | at 2025-01-20 | Standalone | Net assets |
| Net assets / equity | ¥82.4bn | at 2024-01-20v | Standalone | Net assets |
| Net assets / equity | ¥80.5bn | at 2023-01-20v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥80.1bn | at 2022-01-20d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥15.2bn | at 2026-01-20 | Standalone | Cash and deposits |
| Cash and deposits | ¥21.7bn | at 2025-01-20 | Standalone | Cash and deposits |
| EPS (basic) | ¥-825.36 | 2025-01-21 → 2026-01-20 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.35 | 2024-01-21 → 2025-01-20 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.22 | 2023-01-21 → 2024-01-20v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.07 | 2022-01-21 → 2023-01-20v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.88 | 2021-01-21 → 2022-01-20d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥30 | 2025-01-21 → 2026-01-20 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2024-01-21 → 2025-01-20 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2023-01-21 → 2024-01-20v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2022-01-21 → 2023-01-20v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2021-01-21 → 2022-01-20d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,789.67 | at 2026-01-20 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,614.69 | at 2025-01-20 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,618.07 | at 2024-01-20v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,564.03 | at 2023-01-20v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,559.09 | at 2022-01-20d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 58.3% | at 2026-01-20 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2025-01-20 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.0% | at 2024-01-20v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2023-01-20v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2022-01-20d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -37.5% | 2025-01-21 → 2026-01-20 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2024-01-21 → 2025-01-20 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.6% | 2023-01-21 → 2024-01-20v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2022-01-21 → 2023-01-20v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.8% | 2021-01-21 → 2022-01-20d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 33,137,000 | at 2026-01-20 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 33,137,000 | at 2025-01-20 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2024-01-20v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2023-01-20v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2022-01-20d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 52 | at 2026-01-20 | Standalone | Number of employees |
| Employees | 51 | at 2025-01-20 | Standalone | Number of employees |
| Employees | 39 | at 2024-01-20v | Standalone | Number of employees |
| Employees | 26 | at 2023-01-20v | Standalone | Number of employees |
| Employees | 23 | at 2022-01-20d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-01-21 → 2026-01-20 | ¥1.0bn |
| Reconciling Itemsreconciling | depreciation | 2025-01-21 → 2026-01-20 | ¥949m |
| Reconciling Itemsreconciling | revenue | 2025-01-21 → 2026-01-20 | −¥368m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-21 → 2026-01-20 | −¥368m |
| Reconciling Itemsreconciling | segment assets | at 2026-01-20 | ¥34.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-21 → 2026-01-20 | −¥2.1bn |
| Domestic Beverage Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥6.8bn |
| Domestic Beverage Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥6.0bn |
| Domestic Beverage Businessreportable segment | employees | at 2026-01-20 | 3514 pure |
| Domestic Beverage Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥142.7bn |
| Domestic Beverage Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥142.5bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥119m |
| Domestic Beverage Businessreportable segment | segment assets | at 2026-01-20 | ¥43.9bn |
| Domestic Beverage Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | −¥2.3bn |
| Dy Do Pharmareportable segment | capex | 2025-01-21 → 2026-01-20 | ¥20m |
| Dy Do Pharmareportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥61m |
| Dy Do Pharmareportable segment | employees | at 2026-01-20 | 12 pure |
| Dy Do Pharmareportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥606m |
| Dy Do Pharmareportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥606m |
| Dy Do Pharmareportable segment | segment assets | at 2026-01-20 | ¥892m |
| Dy Do Pharmareportable segment | segment profit | 2025-01-21 → 2026-01-20 | −¥321m |
| Food Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥1.3bn |
| Food Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥878m |
| Food Businessreportable segment | employees | at 2026-01-20 | 295 pure |
| Food Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥19.6bn |
| Food Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥19.6bn |
| Food Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥7m |
| Food Businessreportable segment | segment assets | at 2026-01-20 | ¥20.0bn |
| Food Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥487m |
| International Beverage Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥6.2bn |
| International Beverage Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥2.1bn |
| International Beverage Businessreportable segment | employees | at 2026-01-20 | 1147 pure |
| International Beverage Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥65.3bn |
| International Beverage Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥65.3bn |
| International Beverage Businessreportable segment | segment assets | at 2026-01-20 | ¥47.0bn |
| International Beverage Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥7.5bn |
| Pharmaceutical Related Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥1.5bn |
| Pharmaceutical Related Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥1.1bn |
| Pharmaceutical Related Businessreportable segment | employees | at 2026-01-20 | 355 pure |
| Pharmaceutical Related Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥13.4bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥13.2bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥241m |
| Pharmaceutical Related Businessreportable segment | segment assets | at 2026-01-20 | ¥16.9bn |
| Pharmaceutical Related Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥829m |
| —segment total | capex | 2025-01-21 → 2026-01-20 | ¥16.0bn |
| —segment total | depreciation | 2025-01-21 → 2026-01-20 | ¥10.2bn |
| —segment total | revenue | 2025-01-21 → 2026-01-20 | ¥241.6bn |
| —segment total | revenue external | 2025-01-21 → 2026-01-20 | ¥241.2bn |
| —segment total | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥368m |
| —segment total | segment assets | at 2026-01-20 | ¥128.6bn |
| —segment total | segment profit | 2025-01-21 → 2026-01-20 | ¥6.3bn |
| Reconciling Itemsreconciling | capex | 2024-01-21 → 2025-01-20 | ¥597m |
| Reconciling Itemsreconciling | depreciation | 2024-01-21 → 2025-01-20 | ¥796m |
| Reconciling Itemsreconciling | revenue | 2024-01-21 → 2025-01-20 | −¥378m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-21 → 2025-01-20 | −¥378m |
| Reconciling Itemsreconciling | segment assets | at 2025-01-20 | ¥34.5bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-21 → 2025-01-20 | −¥2.1bn |
| Domestic Beverage Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥7.1bn |
| Domestic Beverage Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥5.6bn |
| Domestic Beverage Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥147.5bn |
| Domestic Beverage Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥147.4bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥86m |
| Domestic Beverage Businessreportable segment | segment assets | at 2025-01-20 | ¥74.8bn |
| Domestic Beverage Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥986m |
| Dy Do Pharmareportable segment | capex | 2024-01-21 → 2025-01-20 | ¥382m |
| Dy Do Pharmareportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥21m |
| Dy Do Pharmareportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥8m |
| Dy Do Pharmareportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥8m |
| Dy Do Pharmareportable segment | segment assets | at 2025-01-20 | ¥780m |
| Dy Do Pharmareportable segment | segment profit | 2024-01-21 → 2025-01-20 | −¥621m |
| Food Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥1.2bn |
| Food Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥834m |
| Food Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥20.7bn |
| Food Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥20.6bn |
| Food Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥7m |
| Food Businessreportable segment | segment assets | at 2025-01-20 | ¥21.0bn |
| Food Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥1.2bn |
| International Beverage Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥9.0bn |
| International Beverage Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥1.9bn |
| International Beverage Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥56.3bn |
| International Beverage Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥56.3bn |
| International Beverage Businessreportable segment | segment assets | at 2025-01-20 | ¥37.5bn |
| International Beverage Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥5.1bn |
| Pharmaceutical Related Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥576m |
| Pharmaceutical Related Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥1.4bn |
| Pharmaceutical Related Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥13.1bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥12.8bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥284m |
| Pharmaceutical Related Businessreportable segment | segment assets | at 2025-01-20 | ¥16.6bn |
| Pharmaceutical Related Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥277m |
| —segment total | capex | 2024-01-21 → 2025-01-20 | ¥18.2bn |
| —segment total | depreciation | 2024-01-21 → 2025-01-20 | ¥9.7bn |
| —segment total | revenue | 2024-01-21 → 2025-01-20 | ¥237.6bn |
| —segment total | revenue external | 2024-01-21 → 2025-01-20 | ¥237.2bn |
| —segment total | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥378m |
| —segment total | segment assets | at 2025-01-20 | ¥150.8bn |
| —segment total | segment profit | 2024-01-21 → 2025-01-20 | ¥6.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,846
| Item | Context | Value | Unit |
|---|---|---|---|
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 15 | |
| Number of male directors and other officers | FilingDateInstant | 8 | |
| Number of female directors and other officers | FilingDateInstant | 3 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.27 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000TakamatsuTomiyaMember | 994000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000TonokatsuNaokiMember | 8600 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000NishiyamaNaoyukiMember | 2800 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000InoueMasatakaMember | 200 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000KuriharaMichiakiMember | 200 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000KawanoJunkoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000ItoMinaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000HasegawaNaokazuMember | 5400 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000MoriuchiShigeyukiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000WatanabeKiyoshiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00424-000IshiharaMayumiMember | 200 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 1011400 | |
| Number of male directors and other officers proposal | FilingDateInstant | 8 | |
| Number of female directors and other officers proposal | FilingDateInstant | 3 | |
| Ratio of female directors and other officers proposal | FilingDateInstant | 0.27 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000TakamatsuTomiyaMember | 994000 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000TonokatsuNaokiMember | 8600 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000NishiyamaNaoyukiMember | 2800 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000InoueMasatakaMember | 200 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000KuriharaMichiakiMember | 200 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000KawanoJunkoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000ItoMinaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000HasegawaNaokazuMember | 5400 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000MoriuchiShigeyukiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000WatanabeKiyoshiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E00424-000IshiharaMayumiMember | 200 | |
| Number of shares held ordinary shares information about directors and corporate auditors proposal | FilingDateInstant | 1011400 | |
| Audit fees reporting company | Prior1YearDuration | 94000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | 12000000 | JPY |
| Audit fees reporting company | CurrentYearDuration | 97000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | 1000000 | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | 25000000 | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | 25000000 | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | 39000000 | JPY |
| Audit fees total | Prior1YearDuration | 119000000 | JPY |
| Non audit fees total | Prior1YearDuration | 12000000 | JPY |
| Audit fees total | CurrentYearDuration | 122000000 | JPY |
| Non audit fees total | CurrentYearDuration | 41000000 | JPY |
| Audit fees reporting company network firms | Prior1YearDuration | － | JPY |
| Non audit fees reporting company network firms | Prior1YearDuration | 1000000 | JPY |
| Audit fees reporting company network firms | CurrentYearDuration | － | JPY |
| Non audit fees reporting company network firms | CurrentYearDuration | 2000000 | JPY |
| Audit fees consolidated subsidiaries network firms | Prior1YearDuration | 2000000 | JPY |
| Non audit fees consolidated subsidiaries network firms | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries network firms | CurrentYearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |